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Abstract
Background: Breast magnetic resonance imaging (MRI) is a sensitive method of breast imaging virtually
uninfluenced by breast density. Because of the improved sensitivity, breast MRI is increasingly being used
for detection of breast cancer among high risk young women. However, the specificity of breast MRI is
variable and costs are high. The purpose of this study was to determine if breast MRI is a cost-effective
approach for the detection of breast cancer among young women at high risk.
Methods: A Markov model was created to compare annual breast cancer screening over 25 years with
either breast MRI or mammography among young women at high risk. Data from published studies
provided probabilities for the model including sensitivity and specificity of each screening strategy. Costs
were based on Medicare reimbursement rates for hospital and physician services while medication costs
were obtained from the Federal Supply Scale. Utilities from the literature were applied to each health
outcome in the model including a disutility for the temporary health state following breast biopsy for a
false positive test result. All costs and benefits were discounted at 5% per year. The analysis was performed
from the payer perspective with results reported in 2006 U.S. dollars. Univariate and probabilistic
sensitivity analyses addressed uncertainty in all model parameters.
Results: Breast MRI provided 14.1 discounted quality-adjusted life-years (QALYs) at a discounted cost of
$18,167 while mammography provided 14.0 QALYs at a cost of $4,760 over 25 years of screening. The
incremental cost-effectiveness ratio of breast MRI compared to mammography was $179,599/QALY. In
univariate analysis, breast MRI screening became < $50,000/QALY when the cost of the MRI was < $315.
In the probabilistic sensitivity analysis, MRI screening produced a net health benefit of -0.202 QALYs (95%
central range: -0.767 QALYs to +0.439 QALYs) compared to mammography at a willingness-to-pay
threshold of $50,000/QALY. Breast MRI screening was superior in 0%, < $50,000/QALY in 22%, >
$50,000/QALY in 34%, and inferior in 44% of trials.
Conclusion: Although breast MRI may provide health benefits when compared to mammographic
screening for some high risk women, it does not appear to be cost-effective even at willingness to pay
thresholds above $120,000/QALY.
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In the United States, one in eight women will be diag-
nosed with breast cancer during her lifetime [1]. In 2008,
an estimated 182,460 cases of breast cancer will occur,
accounting for 26% of all cancer cases in women [1] Cur-
rent consensus screening recommendations divide
women into normal and high-risk categories after using
physical examination and clinical judgment as a starting
point [2]. According to the National Comprehensive Can-
cer Network (NCCN) Clinical Practice Guidelines [2,3]
women at increased risk of breast cancer include those
with (i) a history of thoracic or mantle irradiation, (ii) a
strong family history or genetic predisposition, (iii) lobu-
lar carcinoma in situ or atypical hyperplasia, (iv) a prior
history of breast cancer, and/or (v) those over 35 years of
age with a 5-year risk of invasive breast cancer ≥ 1.7%
according to the modified Gail Model. This model calcu-
lates risk based on current age, age at menarche, age at first
live birth, nulliparity, previous breast biopsies, atypical
hyperplasia, and race, though it has not been conclusively
validated in non-Caucasian women [2]. The 5-year risk of
≥ 1.7% is the average risk of a women at the median age
of breast cancer diagnosis in the United States [4]. Women
with a strong family history or genetic disposition are
defined as those with BRCA1/BRCA2 mutations, or a per-
sonal family history of breast cancer and one of several
other familial risk categories, including being diagnosed
before age 40, or before age 50 with one or more close
blood relative with breast cancer, or a close family mem-
ber meeting any of the other criteria [4]. It has been esti-
mated that the risk of developing breast cancer in those
with BRCA1 or BRCA2 mutations is 45% to 65% respec-
tively [4].
The screening algorithms for women at increased risk are
based on the five aforementioned categories. For women
under 25 years of age with a strong family history or
genetic predisposition, the recommendation is for annual
clinical breast examinations and regular breast self-exam-
ination starting at age 18 years [5-7]. The NCCN screening
recommendations for women ≥ 25 years in this risk cate-
gory include annual mammogram and breast MRI screen-
ing starting at age 25, or based on earliest age of onset in
the family, consideration of prophylactic mastectomy,
consideration of chemoprevention options, and consider-
ation of investigational imaging and screening studies [8].
Screening mammography has been shown to reduce mor-
tality from breast cancer by approximately 24% in women
between the ages of 50 and 70 [2]. One modelling study
found that screening decreased the mortality from breast
cancer by 7% – 23%, and that when combined with adju-
vant therapy, the rate declined by 25% – 38% [9-12].
Despite some conflicting evidence, screening recommen-
dations endorse annual mammography in normal risk
women starting at age 40 years [9-12]. In high-risk
women, who tend to develop breast cancer at earlier ages,
however, mammography screening is less sensitive,
largely due to problems detecting cancer in dense breast
tissue. In several studies of high-risk women, including
those with BRCA1 and BRCA2 mutations, yearly screening
mammography had sensitivities ranging from 25% to
36% [13]. Furthermore, observational studies of BRCA
mutation carriers suggest that 50% of breast cancers in
this population present between screening mammograms
[4,7].
MRI is not affected by breast density, and the recent inclu-
sion of breast MRI in the screening guidelines is based on
studies suggesting that high-risk women may benefit from
MRI screening [14]. Several studies have reported the sen-
sitivity of MRI screening in high-risk women to be
between 77% and 91% [14]. Screening with MRI has also
been shown to detect breast cancer in earlier stages in
high-risk women [15]. Unfortunately, spontaneous hor-
mone-induced enhancement may occur, leading to false
positive test results and unnecessary biopsies in women
screened by MRI over mammography. Accordingly, MRI
has lower specificity of 90% as compared to 95% for
mammography [13].
Though MRI is more sensitive than mammography in a
high-risk population, it has not yet been shown to reduce
mortality [16]. MRI is also approximately 10 times more
expensive than mammography and, due to the compara-
tively lower specificity, leads to increased costs in the form
of potentially unnecessary diagnostic examinations, biop-
sies, and anxiety [11]. Although, based on existing evi-
dence, current screening guidelines recommend
consideration of MRI screening in this high-risk popula-
tion [11], its use remains controversial.
Cost-effectiveness analysis, however, can play an impor-
tant role to help determine the role of MRI in screening
women at high-risk for breast cancer. The objective of this
study is to determine the cost-effectiveness of MRI in
screening women with a ≥ 15% cumulative lifetime risk of
breast cancer by using a Markov decision model in a hypo-
thetical cohort of patients.
Methods
Decision Model
We developed a Markov decision model using a hypothet-
ical cohort of patients to compare annual breast cancer
screening over 25 years with either breast MRI or mam-
mography among young women with ≥ 15% cumulative
lifetime risk of breast cancer according to the Claus tables.
The Claus tables is a breast cancer risk assessment tool that
estimates risk based on maternal and paternal family his-
tory, 1st and 2nd degree relatives, age, and family history
of ovarian cancer. The main limitation of this method,Page 2 of 8
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than family history. The Markov model considered one
cycle to be a full year, accounting for each time a patient
underwent screening. In the model, patients are initially
screened with either MRI or mammography. The results of
the diagnostic exam can either show no breast cancer,
node negative breast cancer, or node positive breast can-
cer. In all situations, the patients continue annual screen-
ing until death. Probabilities of living differ for the three
scenarios and, like all other model probabilities including
sensitivity and specificity of each screening strategy, are
based on published literature. The structure of the model
is shown in Figure 1.
Probabilities of MRI and mammography test results and
true positives were distinguished based on BI-RAD scores,
where BI-RADS 0 = "need additional imaging," BI-RADS 3
= "probably benign finding," BI-RADS 4 = "suspicious
abnormality", and BI-RADS 5 = "highly suggestive of
malignancy". Probability ranges were obtained by con-
structing 95% confidence intervals for proportions
derived from the literature using normal approximations
to the binomial distribution. The probabilities used in the
model and ranges explored in univariate sensitivity analy-
ses are shown in Table 1[11,17-22].
Costs
Model costs for physician, hospital and laboratory serv-
ices were based on methodology described in previously
published work [11], using Centers for Medicare & Medic-
aid Services reimbursement data to estimate costs unad-
justed for geographic location and therefore representing
a national average. Medication costs were obtained from
the Federal Supply Scale (FSS). Costs of care and ranges
explored in sensitivity analyses are shown in Table 2
(Additional File 1-Current Procedural Terminology
codes).
Utilities
Model utilities were measured according to quality
adjusted life years (QALY) using values between 0 (death)
and 1 (perfect) based on published literature. Measured
utilities included the utility of having breast cancer, living,
dying, having been diagnosed with node positive breast
cancer, having experienced a false positive examination,
having to experience screening, and having had a false
negative node positive tumor. These utilities were applied
to each health outcome in the model. As seen in the prob-
abilities, ranges for sensitivity analyses were obtained by
constructing 95% confidence intervals for proportions
based on published work. Table 3 contains all base case
probabilities and their respective ranges used in the sensi-
tivity analyses. Neither costs nor outcomes were dis-
counted since costs and benefits all occurred within the
year that resources were utilized and each strategy
required the recurring costs of screening. All outcomes
were discounted at 5% per year, consistent with literature
recommendations [23-25].
Sensitivity Analyses
Univariate sensitivity analyses were performed on each
individual cost, probability and utility in order to explore
the effect that variation in model parameters can have on
the incremental cost-effectiveness of the MRI strategy.
Probabilities and utilities were varied over the ranges
derived from their 95% confidence intervals. Variations in
costs were based on estimated minimums and maximums
from Medicare reimbursement data for hospital, physi-
cian, and laboratory services according to the methodol-
ogy described in recently published work [11]. Costs for
drugs were varied according to the minimum and maxi-
mum medication costs from the FSS. Both low and high
incremental cost-effectiveness ratios (ICERs) were
recorded in univariate analyses and parameters were var-
ied across their distributions in probabilistic sensitivity
analyses. Net health benefit assessments were performed
using a $50,000/QALY willingness-to-pay threshold and
alternative threshold values were examined. The values of
individual model parameters above or below which MRI
became cost-effective were recorded as thresholds. In
addition to the univariate sensitivity analyses, a probabil-
istic sensitivity analysis was performed with 10,000
Monte Carlo simulations to assess the robustness of the
findings in the base case. Confidence ranges for the incre-
mental cost and effectiveness of both screening strategies
were recorded. Normal distributions were used with base
The Markov modelFigure 1
The Markov model. This model considers one cycle to be 
a full year, accounting for each time a patient underwent 
screening. Note that each breast is tracked independently, 
but patient state is determined by occurrence or no occur-
rence of cancer in the first breast.Page 3 of 8
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Table 1: Probabilities used in the model
PROBABILITIES MRI Mammography
Base Case Range Base Case Range
Positive[11] 0.108 0.047–0.169 0.054 0.010–0.098
BI-RADS 0/3[11] 0.856 0.787–0.925 0.898 0.838–0.957
BI-RADS 4/5[11] 0.144 0.075–0.213 0.102 0.043–0.162
True Positive BI-RADS 0/3[11] 0.028 0.000–0.061 0.035 0.000–0.070
False Positive BI-RADS 0/3[11] 0.972 0.939–1.000 0.965 0.930–1.000
Node Positive[11] 0.214 0.134–0.295 0.564 0.467–0.661
Node Negative[17,18] 0.786 0.705–0.866 0.436 0.339–0.533
True Positive BI-RADS 4/5[17,18] 0.323 0.231–0.415 0.478 0.380–0.576
False Positive BI-RADS 4/5[17,18] 0.677 0.585–0.769 0.522 0.424–0.620
False Negative Node Positive[19] 1.000 0.700–1.000 1.000 0.700–1.000
Negative[20] 0.892 0.831–0.953 0.946 0.902–0.990
True Negative[21] 0.997 0.985–1.000 0.993 0.977–1.000
False Negative[21] 0.004 0.000–0.015 0.007 0.000–0.023
Live Node Positive[22] 0.970 0.937–1.000 0.970 0.937–1.000
Live Node Negative 0.990 0.970–1.000 0.990 0.970–1.000
Live no cancer 0.998 0.989–1.000 0.998 0.989–1.000
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System classification
Table 2: Costs used in the model.
PROCEDURES COST ($) RANGE ($)
Local Therapy (Node negative) – Pre-op Evaluation, Lumpectomy with SN biopsy, Lumpectomy Re-excision, 
WBRT-B post lumpectomy (Konski), Mastectomy with SN biopsy, Breast Reconstruction
12,623.41 8,387.27 – 19,405.81
Local Therapy (Node positive) – Pre-op Evaluation, Lumpectomy with SN biopsy/Axillary dissection, 
Lumpectomy Re-excision, WBRT-B post lumpectomy (Konski), Mastectomy with SN biopsy/Axillary 
dissection, Breast Reconstruction
13,590.03 9,487.95–20,909.41
Bilateral Mammography (Screening) 49.76 33.23 – 73.65
Bilateral MRI 965.57 646.60 – 1,432.84
Unilateral Mammography 42.48 28.37 – 62.88
Unilateral MRI 711.72 476.51–1,055.97
Work Up – Ultrasound of Breast, Mammogram of One Breast, FNA Without Imaging, FNA With Imaging, 
Ultrasound-Guided Core Biopsy
591.10 435.49 – 832.66
Systemic Node Positive – CBC, CMP Office/Outpatient Visit New and Established, Heart First Pass (Single), 
Doxarubicin 60 mg/m2, Cyclophosphamide 600 mg/m2, Tamoxifen 180 tabs (Node Pos), Paclitaxel 175 mg/
m2, Trastuzumab 4 mg/kg × 1 = 272 mg (2/3 vial over 90 minutes)
12,923.90 9,955.04–19,851.46
Mammogram BI-RADS 0/3 False Positive 42.48 28.37 – 62.88
MRI BI-RADS 0/3 False Positive 711.72 476.51–1,055.97
Refer to Additional File 1 for the current procedural terminology codes.
Abbreviations: APC, Ambulatory Payment Classification; BI-RADS, Breast Imaging Reporting and Data System classification; CBC, Complete Blood 
Count; CMP, Comprehensive Metabolic Panel; CPT, Current Procedural Terminology; DRG, Diagnosis Related Group; FNA, Fine Needle 
Aspiration; mg/kg, milligram per kilogram; MRI, Magnetic Resonance Imaging; SN, sentinel node; tabs, tablets; WBRT-B, whole breast external beam 
radiation therapy with a boost
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calculated from the high and low ranges for each parame-
ter.
Results
The MRI strategy provided 14.1 QALYs at a discounted
cost of $18,167 while mammography provided 14.0
QALYs at a discounted cost of $4,760 over 25 years of
screening (Table 4). The ICER of MRI compared to mam-
mography was $179,599/QALY. Without discounting,
MRI provided 23.6 QALYs at a cost of $30,380 compared
to 23.4 QALYs for mammography at a cost of $7,765.
Without adjustments for quality-of-life, MRI provided
23.9 life years (14.3 discounted life years) compared to
23.8 life years (14.2 discounted life years) for mammog-
raphy producing a discounted ICER of $146,602/life year.
In univariate analysis, breast MRI screening became <
$50,000/QALY when the cost of the MRI was < $315. Uni-
variate sensitivity analyses are displayed in a tornado dia-
gram of the most influential variables (Figure 2). In this
diagram, each bar represents the impact of uncertainty in
an individual variable on the ICER. Model parameters
that greatly influenced the ICER included the probability
of living with a node negative cancer, and the probabili-
ties associated with positive mammography and MRI
readings. Additional File 2 provides the results for univar-
iate analyses for all model parameters.
In the probabilistic sensitivity analysis, MRI screening
produced a net health benefit of -0.202 QALYs (95% cen-
tral range: -0.767 QALYs to +0.439 QALYs) at a willing-
ness-to-pay threshold of $50,000/QALY. The results of the
probabilistic sensitivity analysis were plotted as an incre-
mental cost-effectiveness scatterplot (Figure 3) to show
the distribution of 10,000 trials from the Monte Carlo
simulation. Each trial point provides a comparison of the
incremental costs and benefits of MRI screening to mam-
mogaphy. For each comparison, parameters for both
screening strategies were simultaneously and randomly
sampled from the probability, cost, and outcome distribu-
tions to account for uncertainty in the base case parameter
estimates. The points could fall in four quadrants; Quad-
rant I, where the MRI screening strategy is both more
costly and more effective than the standard regimen, con-
tained 56% of the samples, 34% had an ICER of greater
than $50,000/QALY and 22% had an ICER > $100,000/
QALY. Quadrant II, where the MRI strategy is more costly
but less effective (inferior), contained 44% of the samples.
Quadrant III represents a situation where MRI screening is
both less costly and less effective while Quadrant IV rep-
resents a situation where the MRI screening strategy is less
costly and more effective (superior). Both Quadrants III
and IV contained no points. The net health benefit accept-
ability curve shows the proportion of trials that attained
cost-effectiveness for a given strategy for willingness-to-
pay thresholds up to $200,000/QALY (Figure 4).
Discussion and conclusion
Breast MRI may provide health benefits when compared
to mammographic screening for some high-risk women;
however, this approach does not appear to be cost-effec-
tive at a willingness-to-pay threshold of $50,000/QALY.
This historical threshold is based on the cost of providing
care to patients with end-stage renal disease in the 1970s,
which now exceeds $120,000/QALY. Given the increased
costs due to increased technology over this time period,
and the benefits to be gained from the use of technologi-
cal advancements, it follows that a higher threshold
would be more appropriate and relevant. In this model,
MRI screening does not approach cost-effectiveness even
if a threshold of $120,000/QALY is used.
Table 3: Utilities and discount rate used in the model
UTILITIES BASE CASE RANGE
Breast Cancer 0.950 0.907 – 0.993
Alive 1.000
Node Positive 0.800 0.722 – 0.878
Dead 0.000
False Positive 0.890 0.829 – 0.951
Screening 0.990 0.970 – 1.000
False Negative Node Positive 0.660 0.567 – 0.753
Discount Rate 0.050 0.00 – 0.050
Table 4: Costs, quality-adjusted life years, cost-effectiveness ratio, and incremental cost-effectiveness ratio of the screening regimens 
over 25 years of screening
Discounted* Undiscounted
STRATEGY COST ($) QALYS ICER ($) COST ($) QALYS ICER ($)
Mammography 4,760 14.0 --- 7,765 23.4 ---
MRI 18,167 14.1 179,599 30,380 23.6 124,291
Discounted at the rate of 5%
Abbreviations: CE, Cost-Effectiveness; ICER, Incremental Cost-Effectiveness Ratio; MRI, Magnetic Resonance Imaging; QALYs, Quality-Adjusted 
Life Years.Page 5 of 8
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were conducted to explore the impact of varying all
resource costs, probabilities, and utilities on the incre-
mental cost-effectiveness of MRI screening. Our model
showed that MRI screening became more cost-effective as
the cost of MRI decreased and the cost of mammography
increased. The cost-effectiveness of MRI screening in this
model strongly depended on several factors, including the
likelihood of survival with node-negative breast cancer,
survival with node-positive breast cancer, positive mam-
mography reading, and positive MRI reading. Therefore,
the model suggests that screening with MRI becomes
more cost-effective for patients with higher-risk profiles,
and as the positive predictive value of MRI screening
increases. Additionally, a probabilistic sensitivity analysis
was performed to assess the robustness of the findings in
the base case. The net health benefits of MRI screening rel-
ative to mammography improve as the willingness-to-pay
threshold approaches $120,000/QALY, but even in this
instance, it did not become cost effective for this popula-
tion.
Other models have shown that MRI screening may be
cost-effective in high-risk women, particularly those with
BRCA1 and BRCA2 mutations. A study, by the UK Mag-
netic Resonance Imaging in Breast Screening Study
Group, of 279 women at high familial risk for breast can-
cer found that the incremental cost per detected cancer in
women with BRCA1 and BRCA2 mutations (n = 117) was
£11,800 (2007 US $24,268) for contrast-enhanced MRI
combined with mammography and £15,300 (2007 US
$31,466) for contrast-enhanced MRI alone compared
with mammography alone [11]. This study included
women aged 35–49 years who tested positive or had a rel-
ative with BRCA1/BRCA2/TP53 mutation or had strong
family history of breast/ovarian cancer. Also this study dif-
fers from our model in that, this study evaluated the cost
effectiveness of MRI alone, mammography alone, and
mammography in combination with MRI.
A recent cost-effectiveness analysis in the US by the Cancer
Intervention and Surveillance Modeling Network consor-
tium, in a simulated cohort of 25 year-old BRCA1 or
Tornado diagram of univariate analysesFigure 2
Tornado diagram of univariate analyses. This Tornado 
diagram shows the degree to which uncertainty in individual 
variables affects ICER.
Incremental cost and effectiveness of MRI over mammogra-phyFigure 3
Incremental cost and effectiveness of MRI over mam-
mography. This scatter plot shows the distribution of 
10,000 trials form the Monte Carlo simulation.
Net health benefit acceptability curvesFigur  4
Net health benefit acceptability curves. This graph 
shows the proportion of trials that attained cost-effective-
ness for a given strategy for willingness-to-pay thresholds up 
to $200,000/QALY.Page 6 of 8
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a threshold of $100,000/QALY gained resulted in MRI
plus mammography screening being cost-effective from
ages 35–54 in women with BRCA1 mutations ($89,661/
QALY; the most cost-effective model in this group was
$43,484/QALY for BRCA1 carriers ages 40–49), and for
women with BRCA2 mutations < 50 years of age with
extremely dense breasts on mammography ($98,454/
QALY) [11,26]. Our study differs from this study in the
patient cohort; we include women at high risk as per the
Claus tables whereas this study only includes women with
BRCA1/BRCA2 mutations. Also, this study evaluates the
cost effectiveness of mammography alone compared to
mammography plus MRI screening. In addition, the prob-
abilities and utilities used in both the above studies are
different from those used in our model.
Our study has some limitations that must be addressed.
There are additional issues relevant to the management of
women at high-risk for breast cancer that were not incor-
porated in the model, and may influence the cost-effec-
tiveness of screening with MRI. For example, although
BRCA mutation carriers may choose to undergo prophy-
lactic mastectomy, many do not choose this option, with
estimates ranging from 0% to 54% of carriers [11,26]. Fur-
thermore, some of the women are also at increased risk for
ovarian cancer. The costs of radiation exposure due to
annual mammography starting at an earlier age were not
incorporated, nor were the costs of possible anxiety and
stress from unnecessary biopsies stemming from false
positive MRI screening. Any or all of these factors might
alter the cost-effectiveness estimate. Finally, the results of
our model should be interpreted with care given that the
results of this cost-effectiveness analysis require compari-
sons to data from observational studies, the Surveillance,
Epidemiology and End Results Program, or clinical trials.
All probabilities and utilities used to populate the model
are estimates derived from the literature. Each of these
estimates carries inherent uncertainty, as does using a
hypothetical cohort. Possible selection bias associated
with utilizing the Claus tables may affect our base case
effectiveness and resource use estimates by either over or
underestimating our base case model parameters. Moreo-
ver, in our probabilistic sensitivity analysis, we did not
assume that a correlation structure existed among the dis-
tributions of the parameters. However, both univariate
and probabilistic sensitivity analyses were performed to
address uncertainty in parameter estimates by exploring
variability in each probability, cost, and outcome esti-
mate.
Although the NCCN screening guidelines for women aged
25 years and older at high-risk for breast cancer include
breast MRI as an adjunctive screening tool to mammo-
grams, breast MRI has not yet been shown to decrease
mortality. Further research into the appropriate role and
cost-effectiveness of screening breast MRI will better eluci-
date which specific risk groups are more likely to benefit
from MRI screening.
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